Inhaled Antibiotics for Ventilator-Associated Pneumonia: A Turning Point

Ventilator-associated pneumonia remains a major challenge in critical care because of its high incidence, prolonged ICU and hospital stays, and escalating health care costs. Conventional intravenous antibiotic therapy is limited by suboptimal lung penetration and systemic toxicity. Inhaled antibiotic therapy offers a promising alternative by delivering high concentrations of drug directly to the site of infection, thereby potentially overcoming biofilm-related resistance mechanisms and improving bacterial eradication. This review examines the epidemiology and clinical burden of ventilator-associated pneumonia, its pathophysiology, and the pharmacokinetic advantages of the inhaled route. Three strategies for inhaled antibiotic therapy-substitutive, adjunctive, and preventive-are discussed. Data from key trials provide proof of concept for prophylactic inhaled therapy, whereas mixed results from adjunctive studies underscore the need for further research. Practical implementation guidelines, such as optimal nebulizer selection, circuit configuration, and essential safety measures, are discussed. Finally, future perspectives on inhaled anti-infectious therapies, including immunomodulators and biologics, are presented. Together, these data support the view that inhaled anti-infective therapy has the potential to transform the management of ventilator-associated pneumonia, although further standardized, large-scale trials are needed to fully establish its clinical efficacy in all situations.